Literature DB >> 6712287

Cancer morbidity in rheumatoid arthritis.

P Prior, D P Symmons, C F Hawkins, D L Scott, R Brown.   

Abstract

A consecutive series of 489 patients with rheumatoid arthritis seen at the centre was studied to determine their cancer morbidity. Overall the 36 cancers diagnosed in the series between 1964 and 1981 were not significantly in excess of the expected number, but there was a highly significant excess of tumours of the reticuloendothelial system. The excess was mainly due to 6 observed cases of lymphoma. We conclude that there is a highly significant association between rheumatoid arthritis and the subsequent development of lymphoproliferative malignancy in this series.

Entities:  

Mesh：

Year:  1984        PMID： 6712287      PMCID： PMC1001446          DOI： 10.1136/ard.43.2.128

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


  10 in total

1.  COURSE AND PROGNOSIS IN RHEUMATOID ARTHRITIS. A FURTHER REPORT.

Authors:  J J DUTHIE; P E BROWN; L H TRUELOVE; F D BARAGAR; A J LAWRIE
Journal:  Ann Rheum Dis       Date:  1964-05       Impact factor: 19.103

2.  THE DEVELOPMENT OF MALIGNANT LYMPHOMA IN THE COURSE OF SJOEGREN'S SYNDROME.

Authors:  N TALAL; J J BUNIM
Journal:  Am J Med       Date:  1964-04       Impact factor: 4.965

3.  Length of life and cause of death in rheumatoid arthritis.

Authors:  S COBB; F ANDERSON; W BAUER
Journal:  N Engl J Med       Date:  1953-10-01       Impact factor: 91.245

4.  Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis.

Authors:  H A Isomäki; T Hakulinen; U Joutsenlahti
Journal:  J Chronic Dis       Date:  1978

5.  The association of rheumatoid arthritis with plasma cell and lymphocytic neoplasms.

Authors:  G J Goldenberg; F Paraskevas; L G Israels
Journal:  Arthritis Rheum       Date:  1969-12

6.  Leukemia or lymphoma occurring subsequent to an autoimmune disease.

Authors:  A Oleinick
Journal:  Blood       Date:  1967-01       Impact factor: 22.113

7.  Increased risk of lymphoma in sicca syndrome.

Authors:  S S Kassan; T L Thomas; H M Moutsopoulos; R Hoover; R P Kimberly; D R Budman; J Costa; J L Decker; T M Chused
Journal:  Ann Intern Med       Date:  1978-12       Impact factor: 25.391

8.  Increased mortality in rheumatoid arthritis.

Authors:  P Allebeck
Journal:  Scand J Rheumatol       Date:  1982       Impact factor: 3.641

9.  Frequency of neoplasia in systemic lupus erythematosus and rheumatoid arthritis.

Authors:  R B Lewis; C W Castor; R E Knisley; G G Bole
Journal:  Arthritis Rheum       Date:  1976 Nov-Dec

10.  Systemic lupus erythematosus and lymphoma.

Authors:  J A Green; A A Dawson; W Walker
Journal:  Lancet       Date:  1978-10-07       Impact factor: 79.321
  10 in total
  38 in total

Review 1.  Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003).

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; M Dougados; P Emery; A Gibofsky; A F Kavanaugh; E C Keystone; L Klareskog; A S Russell; L B A van de Putte; M H Weisman; A F Kavenaugh
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

2.  Leukemia, lymphoma, and multiple myeloma following selected medical conditions.

Authors:  M M Doody; M S Linet; A G Glass; G D Friedman; L M Pottern; J D Boice; J F Fraumeni
Journal:  Cancer Causes Control       Date:  1992-09       Impact factor: 2.506

Review 3.  Rheumatoid arthritis, malignancy, and paraproteins.

Authors:  C Kelly; H Sykes
Journal:  Ann Rheum Dis       Date:  1990-09       Impact factor: 19.103

4.  Safety of extended treatment with anakinra in patients with rheumatoid arthritis.

Authors:  R M Fleischmann; J Tesser; M H Schiff; J Schechtman; G-R Burmester; R Bennett; D Modafferi; L Zhou; D Bell; B Appleton
Journal:  Ann Rheum Dis       Date:  2006-01-05       Impact factor: 19.103

5.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; P Emery; E C Keystone; M H Schiff; P L C M van Riel; M E Weinblatt; M H Weisman
Journal:  Ann Rheum Dis       Date:  2006-11       Impact factor: 19.103

Review 6.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; J Sieper; P Emery; E C Keystone; M H Schiff; P Mease; P L C M van Riel; R Fleischmann; M H Weisman; M E Weinblatt
Journal:  Ann Rheum Dis       Date:  2007-11       Impact factor: 19.103

7.  Incidence of malignancy in Japanese patients with rheumatoid arthritis.

Authors:  Toru Yamada; Ayako Nakajima; Eisuke Inoue; Eiichi Tanaka; Atsuo Taniguchi; Shigeki Momohara; Hisashi Yamanaka
Journal:  Rheumatol Int       Date:  2010-05-16       Impact factor: 2.631

8.  Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study.

Authors:  E Baecklund; A Ekbom; P Sparén; N Feltelius; L Klareskog
Journal:  BMJ       Date:  1998-07-18

9.  Evidence for oligoclonal B cell expansion in the peripheral blood of patients with rheumatoid arthritis.

Authors:  D A Fox; B R Smith
Journal:  Ann Rheum Dis       Date:  1986-12       Impact factor: 19.103

10.  Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT.

Authors:  Anja Strangfeld; Franka Hierse; Rolf Rau; Gerd-Ruediger Burmester; Brigitte Krummel-Lorenz; Winfried Demary; Joachim Listing; Angela Zink
Journal:  Arthritis Res Ther       Date:  2010-01-08       Impact factor: 5.156
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.